PL3272338T3 - Doustna postać dawkowania ketaminy - Google Patents

Doustna postać dawkowania ketaminy

Info

Publication number
PL3272338T3
PL3272338T3 PL17186622T PL17186622T PL3272338T3 PL 3272338 T3 PL3272338 T3 PL 3272338T3 PL 17186622 T PL17186622 T PL 17186622T PL 17186622 T PL17186622 T PL 17186622T PL 3272338 T3 PL3272338 T3 PL 3272338T3
Authority
PL
Poland
Prior art keywords
ketamine
dosage form
oral dosage
oral
dosage
Prior art date
Application number
PL17186622T
Other languages
English (en)
Inventor
Sascha MANTHEI
Helene Rey
Marc Fischer
Olaf MUNDSZINGER
Original Assignee
Develco Pharma Schweiz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develco Pharma Schweiz Ag filed Critical Develco Pharma Schweiz Ag
Publication of PL3272338T3 publication Critical patent/PL3272338T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL17186622T 2014-04-17 2015-04-16 Doustna postać dawkowania ketaminy PL3272338T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14165057 2014-04-17
EP15715764.5A EP3131533B1 (en) 2014-04-17 2015-04-16 Oral dosage form of ketamine
PCT/EP2015/058318 WO2015158854A1 (en) 2014-04-17 2015-04-16 Oral dosage form of ketamine
EP17186622.1A EP3272338B1 (en) 2014-04-17 2015-04-16 Oral dosage form of ketamine

Publications (1)

Publication Number Publication Date
PL3272338T3 true PL3272338T3 (pl) 2021-01-11

Family

ID=50486823

Family Applications (3)

Application Number Title Priority Date Filing Date
PL17186636.1T PL3287124T3 (pl) 2014-04-17 2015-04-16 Doustna postać dawkowania ketaminy
PL15715764T PL3131533T3 (pl) 2014-04-17 2015-04-16 Doustna postać dawkowania ketaminy
PL17186622T PL3272338T3 (pl) 2014-04-17 2015-04-16 Doustna postać dawkowania ketaminy

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL17186636.1T PL3287124T3 (pl) 2014-04-17 2015-04-16 Doustna postać dawkowania ketaminy
PL15715764T PL3131533T3 (pl) 2014-04-17 2015-04-16 Doustna postać dawkowania ketaminy

Country Status (8)

Country Link
US (3) US10335379B2 (pl)
EP (4) EP3287124B1 (pl)
DK (2) DK3272338T3 (pl)
ES (3) ES2935800T3 (pl)
FI (1) FI3287124T3 (pl)
HU (3) HUE051264T2 (pl)
PL (3) PL3287124T3 (pl)
WO (1) WO2015158854A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014240102A1 (en) 2013-03-15 2015-09-17 Janssen Pharmaceutica Nv Pharmaceutical composition of S-ketamine hydrochloride
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
EP3287124B1 (en) * 2014-04-17 2022-11-30 Ketabon GmbH Oral dosage form of ketamine
US20160074340A1 (en) 2014-09-15 2016-03-17 Janssen Pharmaceutica Nv VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
EP3442940A1 (en) 2016-04-11 2019-02-20 Clexio Biosciences Ltd. Deuterated ketamine derivatives
WO2018234568A2 (en) * 2017-06-23 2018-12-27 Develco Pharma Schweiz Ag HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
US10441544B2 (en) 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US10869838B2 (en) 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
CN117531017A (zh) 2017-12-22 2024-02-09 詹森药业有限公司 用于治疗抑郁症的艾司氯胺酮
CN112702995A (zh) 2018-10-05 2021-04-23 克雷西奥生物科技有限公司 治疗重度抑郁症的艾氯胺酮的治疗方案
WO2020178653A1 (en) 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
WO2020225773A1 (en) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
GB2596592A (en) 2020-07-03 2022-01-05 Alkaloid Ad Skopje Pharmaceutical formulation
CN112263572A (zh) * 2020-11-17 2021-01-26 厦门大学附属翔安医院 右旋氯胺酮在制备治疗脱髓鞘疾病药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723614A (en) * 1971-01-06 1973-03-27 Ciba Geigy Ag Maltese-cross scored tablet
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
EP1103256A1 (de) 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
BR0113626A (pt) 2000-08-30 2003-06-17 Pfizer Prod Inc Formulações de liberação sustentada para secretores de hormÈnio do crescimento
AU2008207200B2 (en) * 2007-01-16 2011-02-17 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
US7638651B2 (en) 2007-04-26 2009-12-29 Auspex Pharmaceuticals Substituted cyclohexanones
US20120225949A1 (en) * 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
US20140079740A1 (en) * 2012-08-02 2014-03-20 ClinPharm Support GmbH Oral transmucosal adminstration forms of s-ketamine
JP2016531913A (ja) * 2013-08-26 2016-10-13 アモーサ セラピューティックス， インコーポレイテッドＡｍｏｒｓａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 神経抑制性ケタミンの単層による経口投与
EP3287124B1 (en) * 2014-04-17 2022-11-30 Ketabon GmbH Oral dosage form of ketamine

Also Published As

Publication number Publication date
EP3272338A1 (en) 2018-01-24
HUE051264T2 (hu) 2021-03-01
WO2015158854A1 (en) 2015-10-22
HUE060851T2 (hu) 2023-04-28
EP3287124B1 (en) 2022-11-30
ES2829279T3 (es) 2021-05-31
DK3272338T3 (da) 2020-11-02
EP3131533A1 (en) 2017-02-22
HUE044928T2 (hu) 2019-11-28
FI3287124T3 (fi) 2023-01-13
US20210386691A1 (en) 2021-12-16
US20190290600A1 (en) 2019-09-26
US20170035707A1 (en) 2017-02-09
EP4180030A1 (en) 2023-05-17
ES2743699T3 (es) 2020-02-20
EP3272338B1 (en) 2020-09-09
US11103467B2 (en) 2021-08-31
EP3131533B1 (en) 2019-06-05
EP3287124A1 (en) 2018-02-28
PL3287124T3 (pl) 2023-02-20
US10335379B2 (en) 2019-07-02
ES2935800T3 (es) 2023-03-10
PL3131533T3 (pl) 2019-12-31
DK3131533T3 (da) 2019-09-16

Similar Documents

Publication Publication Date Title
IL287437A (en) Flavociclib solid dosage forms
PL3287124T3 (pl) Doustna postać dawkowania ketaminy
ZA201700301B (en) Solid oral dosage form of lipophilic compounds
IL249946B (en) High Dose Strength Rocaprib Tablets
GB201618482D0 (en) Pharmaceutical compositions
GB201419257D0 (en) Pharmaceutical compositions
IL249553A0 (en) Pharmaceutical preparations
DK3229816T3 (en) Proton-bindende polymerer til oral administration
ZA201700843B (en) Oral pharmaceutical composition of isotretinoin
IL250817A0 (en) pharmaceutical preparations
IL249151A0 (en) A preparation for oral administration
HRP20181406T1 (hr) Farmaceutski dozni oblici
EP3167870C0 (en) TAMPER-PROOF ORAL DOSAGE FORM
ZA201509174B (en) An oral medicinal composition
GB201415811D0 (en) Solid dosage form production
SG2014014872A (en) Pharmaceutical compositions
GB201408432D0 (en) Pharmaceutical compositions